Market Cap 628.96M
Revenue (ttm) 0.00
Net Income (ttm) -80.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 340,400
Avg Vol 186,066
Day's Range N/A - N/A
Shares Out 34.02M
Stochastic %K 15%
Beta 1.02
Analysts Strong Sell
Price Target $39.28

Latest News on AVBP

ArriVent BioPharma Reports Full Year 2024 Financial Results

Mar 3, 2025, 7:00 AM EST - 4 weeks ago

ArriVent BioPharma Reports Full Year 2024 Financial Results


ArriVent BioPharma Reports Second Quarter 2024 Financial Results

Aug 14, 2024, 4:01 PM EDT - 8 months ago

ArriVent BioPharma Reports Second Quarter 2024 Financial Results


ArriVent Appoints John Hohneker, M.D., to its Board of Directors

May 16, 2024, 4:05 PM EDT - 11 months ago

ArriVent Appoints John Hohneker, M.D., to its Board of Directors


ArriVent BioPharma Reports First Quarter 2024 Financial Results

May 8, 2024, 8:00 AM EDT - 11 months ago

ArriVent BioPharma Reports First Quarter 2024 Financial Results


ArriVent Appoints Kristine Peterson to its Board of Directors

Apr 22, 2024, 4:05 PM EDT - 1 year ago

ArriVent Appoints Kristine Peterson to its Board of Directors


ArriVent BioPharma Reports Full Year 2023 Financial Results

Mar 28, 2024, 4:05 PM EDT - 1 year ago

ArriVent BioPharma Reports Full Year 2023 Financial Results